by The Plant-Based Biologics Market is estimated to be valued at Us$ 21.45 Mn in 2023 and is expected to exhibit a CAGR Of 3.4% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Plant-based biologics utilize plant systems such as algae, yeast, plant cell culture or whole plants as bioreactors to produce therapeutic proteins. Compared to traditional biologics produced from mammalian cell culture systems, plant-based systems offer scalability, reduced production costs, and avoidance of issues like pathogen contamination. Some key therapeutic proteins produced using plant systems include monoclonal antibodies, enzymes, vaccines and antibody fragments. As concerns rise regarding sustainability and environmental footprint of conventional biomanufacturing methods, plant-based systems are gaining increased acceptance.
Market Dynamics:
The growth of the plant-based biologics market is aided by two main drivers. Firstly, plants provide scalable, low-cost production platforms compared to traditional cell culture systems. Wide range of plant species such as tobacco, carrot, alfalfa and rice can be used for biomanufacturing and the proteins can be produced on large acreages of land at reduced costs. Secondly, being free from mammalian components, plant-based systems eliminate the risk of contamination from viruses, prions and other pathogens. This provides a safer alternative to products from mammalian sources. The absence of mammalian proteins also reduces the risk of adverse immune reactions, thus increasing patient safety.
Segment Analysis
The plant-based biologics market is primarily segmented into plants and plant systems. Among these, the plants segment currently dominates the market due to the wide availability of plant-based expression systems. Tobacco plants are the most widely used expression system as they allow for high volume production and contain machinery for proper folding and assembly of proteins.
PEST Analysis
Political: Regulations related to biosimilars and biologics are encouraging increased R&D in this market. The FDA has endorsed guidelines for developing plant-based protein products.
Economic: The growing biologics industry and cost benefits of plant-based production over traditional methods are driving market growth.
Social: Increasing acceptance of plant-based therapies and vaccines is supporting the adoption of plant-based biologics.
Technological: Advancements in gene-editing tools and robust plant-based expression platforms are enhancing production yields and efficacy.
Key Takeaways
The Global Plant-Based Biologics Market Demand is expected to witness high growth, exhibiting CAGR of 3.4% over the forecast period 2023 to 2030, due to increasing R&D investments from players. The market size for 2023 is estimated at US$ 21.45 Mn.
Regionally, North America dominates currently due to presence of major players and production facilities. Asia Pacific is projected to witness fastest growth due to rising biopharma industry and expanding research base in China and India.
Key players operating in the plant-based biologics market are Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V. These players are focusing on expanding production capabilities through partnerships.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
